Cargando…

Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes

PURPOSE: Radiotherapy (RT) has played a significant role in treating non melanoma skin cancer (NMSC). High-dose-rate brachytherapy (HDR-BT) approaches have a paramount relevance due to their adaptability, patient protection, and variable dose fractionation schedules. Several innovative applicators h...

Descripción completa

Detalles Bibliográficos
Autores principales: Tormo, Alejandro, Celada, Francisco, Rodriguez, Silvia, Botella, Rafael, Ballesta, Antonio, Kasper, Michael, Ouhib, Zoubir, Santos, Manuel, Perez-Calatayud, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105643/
https://www.ncbi.nlm.nih.gov/pubmed/25097557
http://dx.doi.org/10.5114/jcb.2014.43247
_version_ 1782327408840409088
author Tormo, Alejandro
Celada, Francisco
Rodriguez, Silvia
Botella, Rafael
Ballesta, Antonio
Kasper, Michael
Ouhib, Zoubir
Santos, Manuel
Perez-Calatayud, Jose
author_facet Tormo, Alejandro
Celada, Francisco
Rodriguez, Silvia
Botella, Rafael
Ballesta, Antonio
Kasper, Michael
Ouhib, Zoubir
Santos, Manuel
Perez-Calatayud, Jose
author_sort Tormo, Alejandro
collection PubMed
description PURPOSE: Radiotherapy (RT) has played a significant role in treating non melanoma skin cancer (NMSC). High-dose-rate brachytherapy (HDR-BT) approaches have a paramount relevance due to their adaptability, patient protection, and variable dose fractionation schedules. Several innovative applicators have been introduced to the brachytherapy community. The Valencia applicator is a new superficial device that improves the dose distribution compared with the Leipzig applicator. The purpose of this work is to assess the tumor control, cosmesis, and toxicity in patients with NMSC treated with the Valencia applicator and a new regimen of hypofractionation. MATERIAL AND METHODS: From January 2008 to March 2010, 32 patients with 45 NMSC lesions were treated with the Valencia applicator in the Hospital La Fe. The gross tumor volume was visually assessed, but the tumor depth was evaluated using ultrasound imaging. All lesions for the selected cases were limited to 4 mm depth. The prescription dose was 42 Gy in 6 or 7 fractions (biologically effective dose [BED] ≈ 70 Gy), delivered twice a week. RESULTS: Ninety-eight percent of the lesions were locally controlled at 47 months from treatment. Ninety-three percent of patients were out at least 36 months from treatment. The treatment was well tolerated in all cases. The highest skin toxicity was grade 1 RTOG/EORTC, having resolved with topical treatment at 4 weeks in all but one case which required 2 months. There were no grade 2 or higher late adverse events. CONCLUSIONS: In patients with superficial basal cell carcinoma lesions less than 25 mm in maximum diameter, HDRBT treatment with the Valencia applicator using a hypofractionated regimen provides excellent results, for both cosmetic and local control at a minimum of 3 years follow-up. Moreover, the shorter hypofractionated regimen facilitates compliance, which is very relevant for the elderly patients in our series. Valencia applicators offer a simple, safe, quick, and attractive nonsurgical treatment option.
format Online
Article
Text
id pubmed-4105643
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-41056432014-08-05 Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes Tormo, Alejandro Celada, Francisco Rodriguez, Silvia Botella, Rafael Ballesta, Antonio Kasper, Michael Ouhib, Zoubir Santos, Manuel Perez-Calatayud, Jose J Contemp Brachytherapy Original Paper PURPOSE: Radiotherapy (RT) has played a significant role in treating non melanoma skin cancer (NMSC). High-dose-rate brachytherapy (HDR-BT) approaches have a paramount relevance due to their adaptability, patient protection, and variable dose fractionation schedules. Several innovative applicators have been introduced to the brachytherapy community. The Valencia applicator is a new superficial device that improves the dose distribution compared with the Leipzig applicator. The purpose of this work is to assess the tumor control, cosmesis, and toxicity in patients with NMSC treated with the Valencia applicator and a new regimen of hypofractionation. MATERIAL AND METHODS: From January 2008 to March 2010, 32 patients with 45 NMSC lesions were treated with the Valencia applicator in the Hospital La Fe. The gross tumor volume was visually assessed, but the tumor depth was evaluated using ultrasound imaging. All lesions for the selected cases were limited to 4 mm depth. The prescription dose was 42 Gy in 6 or 7 fractions (biologically effective dose [BED] ≈ 70 Gy), delivered twice a week. RESULTS: Ninety-eight percent of the lesions were locally controlled at 47 months from treatment. Ninety-three percent of patients were out at least 36 months from treatment. The treatment was well tolerated in all cases. The highest skin toxicity was grade 1 RTOG/EORTC, having resolved with topical treatment at 4 weeks in all but one case which required 2 months. There were no grade 2 or higher late adverse events. CONCLUSIONS: In patients with superficial basal cell carcinoma lesions less than 25 mm in maximum diameter, HDRBT treatment with the Valencia applicator using a hypofractionated regimen provides excellent results, for both cosmetic and local control at a minimum of 3 years follow-up. Moreover, the shorter hypofractionated regimen facilitates compliance, which is very relevant for the elderly patients in our series. Valencia applicators offer a simple, safe, quick, and attractive nonsurgical treatment option. Termedia Publishing House 2014-06-03 2014-06 /pmc/articles/PMC4105643/ /pubmed/25097557 http://dx.doi.org/10.5114/jcb.2014.43247 Text en Copyright © 2014 Termedia http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Paper
Tormo, Alejandro
Celada, Francisco
Rodriguez, Silvia
Botella, Rafael
Ballesta, Antonio
Kasper, Michael
Ouhib, Zoubir
Santos, Manuel
Perez-Calatayud, Jose
Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes
title Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes
title_full Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes
title_fullStr Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes
title_full_unstemmed Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes
title_short Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes
title_sort non-melanoma skin cancer treated with hdr valencia applicator: clinical outcomes
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105643/
https://www.ncbi.nlm.nih.gov/pubmed/25097557
http://dx.doi.org/10.5114/jcb.2014.43247
work_keys_str_mv AT tormoalejandro nonmelanomaskincancertreatedwithhdrvalenciaapplicatorclinicaloutcomes
AT celadafrancisco nonmelanomaskincancertreatedwithhdrvalenciaapplicatorclinicaloutcomes
AT rodriguezsilvia nonmelanomaskincancertreatedwithhdrvalenciaapplicatorclinicaloutcomes
AT botellarafael nonmelanomaskincancertreatedwithhdrvalenciaapplicatorclinicaloutcomes
AT ballestaantonio nonmelanomaskincancertreatedwithhdrvalenciaapplicatorclinicaloutcomes
AT kaspermichael nonmelanomaskincancertreatedwithhdrvalenciaapplicatorclinicaloutcomes
AT ouhibzoubir nonmelanomaskincancertreatedwithhdrvalenciaapplicatorclinicaloutcomes
AT santosmanuel nonmelanomaskincancertreatedwithhdrvalenciaapplicatorclinicaloutcomes
AT perezcalatayudjose nonmelanomaskincancertreatedwithhdrvalenciaapplicatorclinicaloutcomes